Home22UA • ETR
add
BioNTech SE ADR
Previous close
€91.20
Day range
€88.80 - €91.15
Year range
€73.15 - €124.90
Market cap
24.81B USD
Avg Volume
25.08K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 260.80M | 102.64% |
Operating expense | 621.10M | -39.74% |
Net income | -386.60M | 52.14% |
Net profit margin | -148.24 | 76.38% |
Earnings per share | -1.60 | 52.38% |
EBITDA | -385.70M | 57.70% |
Effective tax rate | 4.00% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.04B | -18.84% |
Total assets | 21.64B | -2.70% |
Total liabilities | 3.13B | -1.05% |
Total equity | 18.51B | — |
Shares outstanding | 240.40M | — |
Price to book | 1.18 | — |
Return on assets | -5.10% | — |
Return on capital | -5.75% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -386.60M | 52.14% |
Cash from operations | 146.50M | -91.00% |
Cash from investing | -64.40M | 73.32% |
Cash from financing | -13.30M | 41.92% |
Net change in cash | 84.60M | -93.96% |
Free cash flow | -292.96M | -116.69% |
About
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
6,772
